The combined inhibition of both the angiotensin II receptor and neprilysin with a novel drug, LCZ696 (sacubitril/valsartan), was more effective in reducing the risk of death from cardiovascular causes or hospitalization for HF than was ACE inhibition with enalapril in the PARADIGM-HF trial. This evidence concerns the gene MME and hydrops fetalis.